Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives

4 (10 μM): 96% CDK5 inhibition, 98% GSK3 inhibition. Docking models of 4 into CDK5 (A) and GSK3 (B) ATP-binding sites.